// App-Quantinova.ai

: Mertk Inhibition Promotes Anti-Leukemia Immunity By Reversing T Cell Suppression Via the PD-1 Axis

Researchers

Presenter

  • Alisa Lee-Sherick

Principal Investigators

  • Kristen Jacobsen

  • Curtis J. Henry

  • Rebecca Parker

  • Xiaodong Wang

  • Stephen V Frye

  • H. Shelton Earp

  • Deborah DeRyckere

  • Douglas K Graham

Medical Centers

  • Pediatric BMT, University of Colorado AMC, Denver, CO

  • Washington University, St Louis, MO

  • Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA

  • Emory University, Atlanta, GA

  • Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Center for Integrative Chemical Biology and Drug Discovery and Division of Chemical Biology and Medicinal Chemistry, Chapel Hill, NC

  • Department of Nutrition, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

  • Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, GA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 4

  • Programmed cell death 1 ligand 2

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved